Voyager Therapeutics Inc
Voyager Therapeutics Inc (VYGR) Implied Volatility Current
VYGR implied volatility is 244%. IV Rank is 44%, placing current premiums in the middle of their 52-week range.
Read more
Tracking VYGR implied volatility helps you identify when options premiums on Voyager Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Voyager Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when VYGR IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Voyager Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For VYGR, tracking metrics like VYGR IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on VYGR signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.
The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where VYGR implied volatility sits today versus where it has been. Our scanner ranks Voyager Therapeutics Inc implied volatility against its historical range, surfaces extremes in VYGR IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Voyager Therapeutics Inc IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is below its typical range - premiums look reasonable for buyers.
As of September 18, 2026
Trade options with IV on your side
Track VYGR IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→